Please login to the form below

CAR-T therapy

This page shows the latest CAR-T therapy news and features for those working in and with pharma, biotech and healthcare.

Novartis buys CellforCure to bolster cell, gene therapy

Move would make existing partner an in-house capability. As capacity constraints hold back its first CAR-T Kymriah, Novartis has bought a French contract manufacturer to shore up its manufacturing ... It says the deal would “would bolster CAR-T cell

Latest news

CAR-Ts take centre stage as ASH18 comes to a close

Among the highlights, Allogene and partner Servier presented phase 1 data for its ‘off-the-shelf’ CAR-T therapy UCART19 in acute lymphoblastic leukaemia (ALL), making the case for an easier ... There was little expansion of the CAR-T cells in
ASH18: CAR-T and drugs give new options for multiple myeloma

San Diego congress showcasing data in important haematology markets. Celgene and Bluebird Bio’s anti-BCMA CAR-T bb21217 is effective in patients with very advanced multiple myeloma, and crucially seems ... There will be plenty of additional news on
Novartis to relocate UK headquarters to London’s White City

White City has so far attracted the likes of cell therapy biotech Autolus, which was the first major life sciences business to move to the campus in July this year. ... Novartis recently secured rapid market access for its CAR-T therapy Kymriah, via a
Digital tech from Autolus and Oxford BioMedica to speed advanced therapies

The London-based company is developing its own next-generation CAR-T treatments, and has been supported by the government-funded Cell and Gene Therapy Catapult. ... Also receiving funding is Oxford BioMedica, one of the UK’s leading manufacturers of
Novartis: pipeline will generate 60 filings in three years

Mayzent is a follow-up to Novartis’ blockbuster MS therapy Gilenya (fingolimod), which brought in $2.5bn in the first nine months of the year and is facing the threat of ... Already active in this area with its lymphoma and leukaemia CAR-T therapy

More from news
Approximately 4 fully matching, plus 62 partially matching documents found.

Latest Intelligence

Deal Watch October 2018

radioligands and CAR‐T for cancer. $2.1B. Sale. Aurobindo. NovartIs sold part of Sandoz’s US generics. ... Manufacture and supply of CAR‐T cell therapy, Kymriah, for B‐cell acute lymphoblastic leukaemia.
Bluebird Bio: on the cusp of a gene therapy revolution

Bluebird Bio's chief executive Nick Leschly. Cell and gene therapy made the transition from an interesting but unproven science to medical reality in 2017, with two ‘living medicine’ CAR-T ... Its fourth pipeline candidate is the multiple myeloma
No incentive for a cure

These include Kymriah, the pioneering CAR-T cell therapy from Novartis, which demonstrated a remarkable 83% remission rate in children and young adults with B-cell precursor acute lymphoblastic leukaemia. ... One of the biggest questions with a curative
Can value-based healthcare take off and reach for the skies?

CAR-T cell therapy for children with B-cell ALL. ... costs. It was then backed with a ‘no response-no payment’ contract. It has also struck novel reimbursement packages with its heart failure therapy Entresto and its psoriasis treatment Cosentyx.
The rise of real-world evidence

Novartis secured such an outcome-based model for its CAR-T therapy Kymriah. ... Spark Therapeutics has a similar arrangement for its gene therapy. These agreements make real-world efficacy a requirement for full payment for a drug.

More from intelligence
Approximately 0 fully matching, plus 17 partially matching documents found.

Latest appointments

Marinomed appoints CFO, Robin Brown is named chair of Medicines Discovery Catapult and more

Ceylad appoints new CFO. Clinical-stage biopharma focused on the development of CAR-T cell therapies has announced that Filippo Petti has been appointed as Chief Financial Officer. ... He said: “Celyad’s differentiated approach to the field of CAR-T

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

Highlights in haematologic malignancy from ASH 2018

The spotlight shone on Chimeric Antigen Receptor(CAR) T-cell therapy; a transformative approach where the patient’s T cells are harvested and re-engineered to recognise antigens expressed by the ... A reduced risk of relapse was also seen when
Training the next generation of biotech leaders

In this year alone, the FDA has taken the groundbreaking step of approving two CAR-T therapies. ... In August, Novartis’ revolutionary CAR-T therapy, Kymriah, was approved. This was quickly followed by the approval of Kite’s Yescarta in October.
Innovation in pharma: the highs and lows of the current healthcare economy

Gene therapies often require a ‘one-time only’ treatment offering life-changing potential to patients with conditions where currently there may be no available therapy at all, for instance, in rare ... Also in cancers: chimeric antigen receptor T

More from PMHub
Approximately 0 fully matching, plus 3 partially matching documents found.

Featured jobs

Technical Manager – Developer and Commercial Excellence, Healthc...: Excellent package

Client Services Director – Medical Education Agency – North West...: Salary TBC

Editorial Assistant Medical Education Agency: £25, 000 - £26, 000

Account Manager / Senior Account Manager: 35, 000-40, 000

Account Director, Healthcare Marketing Agency: Salary TBC

Engagement Expert, Healthcare Brand Communications, London: Excellent package

Account Director – Health Policy – Global Agency: Salary TBC

Senior Account Manager, Rare Diseases – Medical Communications, ...: Excellent package

Associate Director: £75, 000-90, 000

Global Business Development Director – Health Education: excellent commission

Engagement Specialist, Healthcare Brand Communications, London, ...: circa £50K

Home-based Senior Project Manager – Independent Med Ed: Salary TBC

Senior Account Manager: Competitive Salary Offered

Senior Medical Writer: Salary TBC

Account Director, Medical Education: Salary TBC

Account Director – Healthcare Marketing – Berks: Salary TBC

Account Manager / Account Director: Competative

PRINCIPAL MEDICAL WRITER > ETL - LONDON / NEW YORK/ HOME - ME...: Salary TBC

Senior Director – Healthcare PR – Global Agency: Salary TBC

Medical Writer: Salary TBC

Senior Account Director development role to Business Director, H...: Excellent package

Account Director: Competitive Salary Offered

Business Director: Competitive Salary Offered

Subscribe to our email news alerts

PMHub

Add my company

Wisepress

Wisepress is a medical bookseller promoting and selling books worldwide, both online and via the 200 European medical conferences that...

Latest intelligence

The UK’s new five-year pricing agreement: Pharma has agreed to capped growth again - in exchange for uptake promises...
Digital applications are transforming the market access landscape: Organisations are leveraging new technology to implement a wider range of business models and, in essence, drive market access success by working smarter, faster and with greater economy....
Escaping the spin cycle of sub-optimal launch: ...